{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:17:39Z","timestamp":1786119459641,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1097\/mcg.0b013e3181c115b3","type":"journal-article","created":{"date-parts":[[2010,3,26]],"date-time":"2010-03-26T05:37:43Z","timestamp":1269581863000},"page":"371-373","source":"Crossref","is-referenced-by-count":56,"title":["Bezafibrate Treatment of Primary Biliary Cirrhosis Following Incomplete Response to Ursodeoxycholic Acid"],"prefix":"10.1097","volume":"44","author":[{"given":"Rawi","family":"Hazzan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Tur-Kaspa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210305","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/01.mcg.0000225653.07932.8f","article-title":"Clinical epidemiology of primary biliary cirrhosis: incidence, prevalence, and impact of therapy","volume":"41","author":"Lazaridis","year":"2007","journal-title":"J Clin Gastroenterol"},{"key":"R2-13-20210305","first-page":"237","article-title":"Tissue antibodies in primary biliary cirrhosis, active chronic (lupoid) hepatitis, cryptogenic cirrhosis and other liver diseases and their clinical implications","volume":"1","author":"Doniach","year":"1966","journal-title":"Clin Exp Immunol"},{"key":"R3-13-20210305","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology"},{"key":"R4-13-20210305","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/0016-5085(85)90213-6","article-title":"Beneficial effect of azathioprine and prediction prognosis in primary biliary cirrhosis: final results of an international trial","volume":"89","author":"Christensen","year":"1985","journal-title":"Gastroenterology"},{"key":"R5-13-20210305","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0016-5085(93)90422-9","article-title":"Cyclosporin A treatment in primary biliary cirrhosis: results of long-term placebo controlled trial","volume":"104","author":"Lombard","year":"1993","journal-title":"Gastroenterology"},{"key":"R6-13-20210305","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/hep.20897","article-title":"Methotrexate (MTX) plus ursodeoxycholic acid for treatment of primary biliary cirrhosis","volume":"42","author":"Combes","year":"2005","journal-title":"Hepatology"},{"key":"R7-13-20210305","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1111\/j.1572-0241.2005.41522.x","article-title":"Colchicine for primary liver cirrhosis: a cochrane hepato-biliary group systematic review of randomized clinical trials","volume":"100","author":"Gong","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R8-13-20210305","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1272\/jnms1923.63.424","article-title":"A lipid lowering drug (bezafibrate) has a favorable effect on liver enzymes (AL-P and gamma-GTP)","volume":"63","author":"Fukuo","year":"1996","journal-title":"Nippon Ika Daigaku Zasshi"},{"key":"R9-13-20210305","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology"},{"key":"R10-13-20210305","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1042\/bj3140781","article-title":"Fibrates induce MDR2 gene expression and biliary phospolipid secretion in the mouse","volume":"314","author":"Chianale","year":"1996","journal-title":"Biochem J"},{"key":"R11-13-20210305","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0168-8278(97)80469-2","article-title":"Overexpression of MDR2 gene by peroisome proliferation in the mouse liver","volume":"26","author":"Miranda","year":"1997","journal-title":"J Hepatol"},{"key":"R12-13-20210305","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/31701","article-title":"Activation of human aortic smooth-muscle cells is inhibited by PPAR alfa but not by PPAR gama activators","volume":"393","author":"Staels","year":"1998","journal-title":"Nature"},{"key":"R13-13-20210305","doi-asserted-by":"crossref","first-page":"211","DOI":"10.5551\/jat.12.211","article-title":"A nuclear receptor-mediated choleretic action of fibrates is associated with enhanced membrane fluidity and transporter activity mediating bile acid-independent bile secretion","volume":"12","author":"Nishiyoka","year":"2005","journal-title":"J Atheroscler Thromb"},{"key":"R14-13-20210305","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/384039a0","article-title":"The PPAR alpha-leukotriene B4 pathway to inflammation control","volume":"384","author":"Devchand","year":"1996","journal-title":"Nature"},{"key":"R15-13-20210305","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1572-0241.2000.01667.x","article-title":"Combination therapy of bezafibrate and ursodeoxycholic acidin primary biliary cirrhosis: a preliminary study","volume":"95","author":"Nakai","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R16-13-20210305","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s00535-004-1583-7","article-title":"Long-term fibrate treatment for PBC","volume":"40","author":"Nakamuta","year":"2005","journal-title":"J Gastroenterol"},{"key":"R17-13-20210305","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00535-006-1778-1","article-title":"Long-term effect of bezafibrate on parameters of hepatic fibrosis in primay biliary cirrhosis","volume":"41","author":"Ohmoto","year":"2006","journal-title":"J Gastroenterol"},{"key":"R18-13-20210305","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00535-002-1102-7","article-title":"Bezafibrate treatment: a new medical approach for PBC patients?","volume":"38","author":"Kanda","year":"2003","journal-title":"J Gastroenterol"},{"key":"R19-13-20210305","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s00535-006-1831-0","article-title":"Bezafibrate may attenuate biliary damage associate with chronic liver diseases accompanied by high serum biliary enzyme level","volume":"41","author":"Kita","year":"2006","journal-title":"J Gastroenterol"},{"key":"R20-13-20210305","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1572-0241.2002.05645.x","article-title":"Is bezafibrate histologically effective for primary biliary cirrhosis?","volume":"97","author":"Yano","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R21-13-20210305","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1572-0241.2002.05413.x","article-title":"Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy","volume":"97","author":"Kurihara","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R22-13-20210305","first-page":"83","article-title":"Effect of bezafibrate in the treatment of primay biliary cirrhosis","volume":"61","author":"Kurihara","year":"1999","journal-title":"Curr Ther Res"},{"key":"R23-13-20210305","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1111\/j.1572-0241.2000.03220.x","article-title":"Bezafibrate in the treatment of primary biliary cirrhosis","volume":"95","author":"Kurihara","year":"2000","journal-title":"Am J Gastroenterol"}],"container-title":["Journal of Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MCG.0b013e3181c115b3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:12:41Z","timestamp":1786039961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004836-201005000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/mcg.0b013e3181c115b3","relation":{},"ISSN":["0192-0790"],"issn-type":[{"value":"0192-0790","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}